Located on the tips of the Y-shaped molecule, the framework regions are responsible for acting as a scaffold for the complementarity determining regions (CDR), also referred to as hypervariable regions, of the Fab.

Complementarity-determining regions (CDRs) are polypeptide segments of the variable chains in immunoglobulins (antibodies) and T cell receptors, generated by B-cells and T-cells respectively. CDRs are where these molecules bind to their specific antigen and their structure/sequence determines the binding activity of the respective antibody.

Here, we describe the humanization of an anti-myostatin antibody utilizing a 2-step process of traditional CDR-grafting onto a human acceptor framework, followed by a structure-guided approach to further reduce the murine content of CDR-grafted antibodies.

Complementarity-determining regions (CDRs) are immunoglobulin (Ig) hypervariable domains that determine specific antibody (Ab) binding. We have shown that synthetic CDR-related peptides and many decapeptides spanning the variable region of a recombinant yeast killer toxin-like antiidiotypic Ab are candidacidal in vitro.

We evaluated a library of CDR–framework combinations for expression, physiochemical properties, binding affinity, target engagement, and function. Sequence homology between the human and original mouse framework regions appeared to exhibit a critical minimum threshold for robust expression.

We expand on this approach by grafting the complementary determining regions (CDRs) of a mouse anti-LAG3 antibody into an extensive matrix of human variable heavy chain (VH) and variable light chain (VL) framework re-gions with substantially broader sequence homology to assess the impact on complementary determining region–framework compatibilit...

We expand on this approach by grafting the complementary determining regions (CDRs) of a mouse anti-LAG3 antibody into an extensive matrix of human variable heavy chain (VH) and variable light chain (VL) framework regions with substantially broader sequence homology to assess the impact on complementary determining region-framework ...

CD&R is the 24th oldest private equity firm in the world. CD&R has managed the investment of more than $30 billion in approximately 90 businesses, representing a broad range of industries with an aggregate transaction value in excess of $140 billion.

Jan 26, 2023 · Having obtained the full-length sequence of an antibody, it is important to identify which portions of the sequence correspond to the CDR loops and which to the framework regions.

CD&R primarily invests in the private equity asset class, with its latest flagship fund raised at $16B in 2021. CD&R focuses on the industries of business services, consumer/retail, financial services, healthcare, industrials, and technology.